US2024000832A1PendingUtilityA1
Treatment and prevention of injury due to radiation exposure
Est. expiryJul 6, 2038(~12 yrs left)· nominal 20-yr term from priority
Inventors:Elsa ComptePatrick MaurelSophie Grives-JerphagnonCyril LavaudLorraine Benigno-AntonJean-Claude Maurel
A61K 33/32A61P 39/00A61K 9/1075A61K 47/10A61K 47/14A61K 47/24A61K 47/28A61K 33/04A61K 33/00A61K 33/30A61N 2005/1098
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The disclosure relates to the treatment and/or prevention of radiation damage by administering a reverse micelle system.
Claims
exact text as granted — not AI-modified1 - 23 . (canceled)
24 . A reverse micellar system comprising at least a sterol, 50 to 90% of acylglycerol, 1 to 20% of lecithin, ethanol and water, and the weight ratio of lecithin to acylglycerol is from 0.05:1 to 0.4:1,
wherein the reverse micellar system is free of a chelator, wherein the reverse micellar system is free of cyano-bridged metal nanoparticles, and wherein the reverse micellar system comprises at least 300 μg/g of manganese.
25 . The reverse micellar system of claim 24 , comprising 5 to 15% lecithin.
26 . The reverse micellar system of claim 24 , wherein the reverse micellar system is free of DTPA, bisphosphonates, Prussian blue, EDTA, Trientine, D-penicillamine, Deferoxamine, BAL, DMSA, DMPS, Phytic acid, Hydroxypyridonates (HOPO), mercaptoacetyltriglycine (MAG3), chelating peptides, derivatives thereof and combinations thereof.
27 . The reverse micellar system of claim 25 , wherein the reverse micellar system is free of DTPA, bisphosphonates, Prussian blue, EDTA, Trientine, D-penicillamine, Deferoxamine, BAL, DMSA, DMPS, Phytic acid, Hydroxypyridonates (HOPO), mercaptoacetyltriglycine (MAG3), chelating peptides, derivatives thereof and combinations thereof.Join the waitlist — get patent alerts
Track US2024000832A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.